February 3, 2020
Ono Pharmaceutical suffered a 4.7% sales decline for its flagship PD-1 inhibitor Opdivo (nivolumab) in April-December as its label expansions failed to counter its 37.5% price cut in November 2018 and ever-intensifying competition on the market. Despite the fall, the...read more